Symbols / ALMR Stock $20.61 +4.30% Alamar Biosciences, Inc.

Healthcare • Medical Devices • United States • NMS
ALMR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Dr. Yuling Luo Ph.D.
Exch · Country NMS · United States
Market Cap 1.43B
Enterprise Value 1.65B
Income -43.48M
Sales 87.16M
FCF (ttm) —
Book/sh -2.57
Cash/sh 0.93
Employees 222
Insider 10d —
IPO Apr 17, 2026
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -29.29
PEG —
P/S 16.39
P/B -8.02
P/C —
EV/EBITDA -51.29
EV/Sales 18.88
Quick Ratio 3.50
Current Ratio 5.88
Debt/Eq 185.42
LT Debt/Eq —
EPS (ttm) -0.65
EPS next Y -0.70
EPS Growth —
Revenue Growth 98.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) —
ROA —
ROE —
ROIC —
Gross Margin 57.11%
Oper. Margin -47.42%
Profit Margin -49.89%
Shs Outstand 69.31M
Shs Float 38.15M
Insider Own 26.67%
Instit Own 28.31%
Short Float 3.98%
Short Ratio 3.16
Short Interest 1.15M
52W High 27.20
vs 52W High -24.23%
52W Low 18.85
vs 52W Low 9.34%
Beta —
Impl. Vol. —
Rel Volume 0.26
Avg Volume 458.31K
Volume 119.83K
Target (mean) $30.00
Tgt Median $30.00
Tgt Low $27.00
Tgt High $35.00
# Analysts 5
Recom None
Prev Close $19.76
Price $20.61
Change 4.30%
About

Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. The company was incorporated in 2018 and is based in Fremont, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$30.00
Mean price target
2. Current target
$20.61
Latest analyst target
3. DCF / Fair value
$30.00
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$20.61
Low
$27.00
High
$35.00
Mean
$30.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-12 init Leerink Partners — → Outperform $35
2026-05-12 init TD Cowen — → Buy $30
2026-05-12 init JP Morgan — → Overweight $30
2026-05-12 init Stifel — → Buy $28
News
RSS: Latest ALMR news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31
Total Revenue
74.21
+195.17%
25.14
Operating Revenue
73.71
+193.18%
25.14
Cost Of Revenue
32.51
+96.59%
16.54
Reconciled Cost Of Revenue
32.51
+96.59%
16.54
Gross Profit
41.70
+384.55%
8.61
Operating Expense
73.04
+25.55%
58.17
Research And Development
37.47
-4.49%
39.23
Selling General And Administration
35.57
+87.78%
18.94
Total Expenses
105.55
+41.27%
74.71
Operating Income
-31.33
+36.79%
-49.57
Total Operating Income As Reported
-31.33
+36.79%
-49.57
EBITDA
-24.89
+40.44%
-41.79
Normalized EBITDA
-24.89
+40.44%
-41.79
Reconciled Depreciation
3.86
+20.98%
3.19
EBIT
-28.75
+36.08%
-44.98
Net Income
-29.82
+36.65%
-47.07
Pretax Income
-29.15
+38.05%
-47.06
Net Non Operating Interest Income Expense
1.76
-32.27%
2.60
Interest Expense Non Operating
0.40
-80.70%
2.08
Net Interest Income
1.76
-32.27%
2.60
Interest Expense
0.40
-80.70%
2.08
Interest Income Non Operating
2.16
-53.80%
4.67
Interest Income
2.16
-53.80%
4.67
Other Income Expense
0.42
+573.03%
-0.09
Other Non Operating Income Expenses
0.42
+573.03%
-0.09
Tax Provision
0.67
+5015.38%
0.01
Tax Rate For Calcs
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
Net Income Including Noncontrolling Interests
-29.82
+36.65%
-47.07
Net Income From Continuing Operation Net Minority Interest
-29.82
+36.65%
-47.07
Net Income From Continuing And Discontinued Operation
-29.82
+36.65%
-47.07
Net Income Continuous Operations
-29.82
+36.65%
-47.07
Normalized Income
-29.82
+36.65%
-47.07
Net Income Common Stockholders
-29.82
+36.65%
-47.07
Diluted EPS
-0.45
+36.65%
-0.71
Basic EPS
-0.45
+36.65%
-0.71
Basic Average Shares
66.52
+0.00%
66.52
Diluted Average Shares
66.52
+0.00%
66.52
Diluted NI Availto Com Stockholders
-29.82
+36.65%
-47.07
Line Item Trend 2025-12-31 2024-12-31
Total Assets
139.99
-6.37%
149.51
Current Assets
94.70
-11.24%
106.70
Cash Cash Equivalents And Short Term Investments
30.00
-62.19%
79.36
Cash And Cash Equivalents
30.00
+12.07%
26.77
Other Short Term Investments
0.00
-100.00%
52.59
Receivables
12.75
+74.17%
7.32
Accounts Receivable
12.75
+91.83%
6.65
Other Receivables
—
0.67
Inventory
38.48
+167.09%
14.41
Raw Materials
24.74
+171.16%
9.12
Work In Process
2.92
+171.72%
1.07
Finished Goods
10.82
+157.07%
4.21
Other Current Assets
13.47
+140.11%
5.61
Total Non Current Assets
45.29
+5.78%
42.81
Net PPE
36.63
+4.36%
35.10
Gross PPE
44.97
+10.60%
40.65
Accumulated Depreciation
-8.34
-50.03%
-5.56
Properties
0.00
0.00
Machinery Furniture Equipment
16.76
+29.65%
12.93
Other Properties
27.15
-1.54%
27.57
Leases
1.05
+597.35%
0.15
Goodwill And Other Intangible Assets
1.99
-2.74%
2.04
Other Intangible Assets
1.99
-2.74%
2.04
Other Non Current Assets
6.67
+17.59%
5.67
Total Liabilities Net Minority Interest
298.95
+5.66%
282.92
Current Liabilities
23.73
+43.03%
16.59
Payables And Accrued Expenses
13.57
+56.29%
8.68
Payables
5.87
-5.09%
6.19
Accounts Payable
5.87
-5.09%
6.19
Current Accrued Expenses
7.70
+208.45%
2.50
Pensionand Other Post Retirement Benefit Plans Current
6.86
+26.45%
5.42
Current Debt And Capital Lease Obligation
2.10
+9.84%
1.91
Current Capital Lease Obligation
2.10
+9.84%
1.91
Current Deferred Liabilities
1.20
+109.39%
0.57
Current Deferred Revenue
0.47
-18.26%
0.57
Total Non Current Liabilities Net Minority Interest
275.22
+3.34%
266.33
Long Term Debt And Capital Lease Obligation
39.37
+26.24%
31.19
Long Term Debt
9.81
—
Long Term Capital Lease Obligation
29.56
-5.21%
31.19
Other Non Current Liabilities
0.60
—
Preferred Securities Outside Stock Equity
235.00
+0.00%
235.00
Stockholders Equity
-158.95
-19.15%
-133.41
Common Stock Equity
-158.95
-19.15%
-133.41
Capital Stock
0.00
+0.00%
0.00
Common Stock
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
Share Issued
66.52
+0.00%
66.52
Ordinary Shares Number
66.52
+0.00%
66.52
Additional Paid In Capital
9.89
+83.35%
5.39
Retained Earnings
-168.78
-21.46%
-138.96
Gains Losses Not Affecting Retained Earnings
-0.07
-148.32%
0.15
Other Equity Adjustments
-0.07
-148.32%
0.15
Total Equity Gross Minority Interest
-158.95
-19.15%
-133.41
Total Capitalization
-149.14
-11.79%
-133.41
Working Capital
70.97
-21.23%
90.11
Invested Capital
-149.14
-11.79%
-133.41
Total Debt
41.47
+25.29%
33.10
Capital Lease Obligations
31.66
-4.34%
33.10
Net Tangible Assets
-160.94
-18.82%
-135.46
Tangible Book Value
-160.94
-18.82%
-135.46
Derivative Product Liabilities
0.25
+70.34%
0.14
Line Item Trend 2025-12-31 2024-12-31
Operating Cash Flow
-53.61
+2.91%
-55.21
Cash Flow From Continuing Operating Activities
-53.61
+2.91%
-55.21
Net Income From Continuing Operations
-29.82
+36.65%
-47.07
Depreciation Amortization Depletion
3.86
+20.98%
3.19
Depreciation And Amortization
3.86
+20.98%
3.19
Other Non Cash Items
2.13
+27.82%
1.66
Stock Based Compensation
2.87
+228.75%
0.87
Operating Gains Losses
0.04
+320.00%
0.01
Gain Loss On Investment Securities
0.10
+920.00%
0.01
Net Foreign Currency Exchange Gain Loss
-0.06
0.00
Change In Working Capital
-32.57
-171.67%
-11.99
Change In Receivables
-5.50
-7.85%
-5.10
Changes In Account Receivables
-5.91
-26.17%
-4.68
Change In Inventory
-23.78
-171.69%
-8.75
Change In Prepaid Assets
-6.44
-186.82%
-2.25
Change In Payables And Accrued Expense
5.81
-9.23%
6.41
Change In Accrued Expense
6.39
+83.08%
3.49
Change In Payable
-0.57
-119.61%
2.92
Change In Account Payable
-0.57
-119.61%
2.92
Change In Other Current Assets
-0.75
-10.52%
-0.68
Change In Other Current Liabilities
-1.92
-18.18%
-1.62
Investing Cash Flow
46.18
+185.62%
-53.93
Cash Flow From Continuing Investing Activities
46.18
+185.62%
-53.93
Net PPE Purchase And Sale
-5.37
-82.26%
-2.95
Purchase Of PPE
-5.37
-82.26%
-2.95
Capital Expenditure
-6.38
-88.43%
-3.39
Capital Expenditure Reported
-1.01
-129.77%
-0.44
Net Investment Purchase And Sale
52.56
+203.99%
-50.55
Purchase Of Investment
-4.94
+94.66%
-92.53
Sale Of Investment
57.50
+36.96%
41.98
Financing Cash Flow
10.84
-90.45%
113.42
Cash Flow From Continuing Financing Activities
10.84
-90.45%
113.42
Net Issuance Payments Of Debt
10.00
+166.67%
-15.00
Issuance Of Debt
10.00
0.00
Repayment Of Debt
0.00
+100.00%
-15.00
Long Term Debt Issuance
10.00
0.00
Long Term Debt Payments
0.00
+100.00%
-15.00
Net Long Term Debt Issuance
10.00
+166.67%
-15.00
Short Term Debt Issuance
10.00
0.00
Net Short Term Debt Issuance
10.00
0.00
Net Common Stock Issuance
1.49
+58.83%
0.94
Net Other Financing Charges
-0.66
—
Changes In Cash
3.40
-20.28%
4.27
Effect Of Exchange Rate Changes
-0.17
-17100.00%
-0.00
Beginning Cash Position
31.68
+15.58%
27.41
End Cash Position
34.91
+10.20%
31.68
Free Cash Flow
-59.99
-2.37%
-58.60
Interest Paid Supplemental Data
0.13
-93.62%
2.05
Amortization Of Securities
-0.12
+93.56%
-1.89
Common Stock Issuance
1.49
+58.83%
0.94
Issuance Of Capital Stock
1.49
-98.84%
128.42
Net Preferred Stock Issuance
0.00
-100.00%
127.48
Preferred Stock Issuance
0.00
-100.00%
127.48
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category